Informazione:
Errore:
ID
14960
Descrizione
A Phase II Trial of Lapatinib (TYKERB) + Pemetrexed (ALIMTA) in Advanced Non Small Cell Lung Cancer With an Initial Dose Finding Phase; ODM derived from: https://clinicaltrials.gov/show/NCT00528281
collegamento
https://clinicaltrials.gov/show/NCT00528281
Keywords
versioni (1)
- 09/05/16 09/05/16 -
Caricato su
9 maggio 2016
DOI
Per favore, per richiedere un accesso.
Licenza
Creative Commons BY 4.0
Commenti del modello :
Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.
Commenti del gruppo di articoli per :
Commenti dell'articolo per :
Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.
Eligibility Advanced Non-Small Cell Lung Cancer NCT00528281
Eligibility Advanced Non-Small Cell Lung Cancer NCT00528281
- StudyEvent: Eligibility
Similar models
Eligibility Advanced Non-Small Cell Lung Cancer NCT00528281
- StudyEvent: Eligibility
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
informed consent
Item
Written informed consent
boolean
C0021430 (UMLS CUI [1])
age
Item
patients must be 18 years old
boolean
C0001779 (UMLS CUI [1])
nsclc
Item
subjects must have stage iiib or iv nsclc
boolean
C0007131 (UMLS CUI [1])
cytotoxic chemotherapy
Item
recurrent or persistent nsclc following one previous line of cytotoxic chemotherapy
boolean
C0677881 (UMLS CUI [1])
ecog
Item
eastern cooperative oncology group (ecog) performance status (ps) 0-2;
boolean
C1520224 (UMLS CUI [1])
life expectancy
Item
life expectancy of 12 weeks
boolean
C0023671 (UMLS CUI [1])
organ function
Item
have adequate organ function baseline laboratory values for inclusion
boolean
C0678852 (UMLS CUI [1])
malignancy
Item
history of other malignancy. subjects who have been disease-free for 5 years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible;
boolean
C0455471 (UMLS CUI [1])
central nervous system metastases
Item
known history of or clinical evidence of central nervous system (cns) metastases or leptomeningeal carcinomatosis except for individuals who have previously treated cns metastases, are asymptomatic, and have had no requirement for steroids or antiseizure medication for = 3 months prior to study enrollment.
boolean
C0686377 (UMLS CUI [1])
peripheral neuropathy
Item
peripheral neuropathy of grade 3 or higher
boolean
C0031117 (UMLS CUI [1])
cconcurrent ancer therapy
Item
concurrent cancer therapy (chemotherapy, radiation therapy, surgery, immunotherapy, biologic therapy, hormonal therapy, and tumor embolization).
boolean
C0205420 (UMLS CUI [1,1])
C0920425 (UMLS CUI [1,2])
C0920425 (UMLS CUI [1,2])
pemetrexed
Item
prior exposure to pemetrexed or an egfr inhibitor in combination with 5-fu or a 5fu prodrug.
boolean
C0210657 (UMLS CUI [1])